Q1 EPS Estimates for Nuvation Bio Boosted by HC Wainwright

Nuvation Bio Inc. (NYSE:NUVB) – HC Wainwright boosted their Q1 2026 earnings per share estimates for Nuvation Bio in a research report issued on Monday, January 12th. HC Wainwright analyst R. Burns now forecasts that the company will post earnings per share of ($0.11) for the quarter, up from their prior estimate of ($0.12). HC Wainwright has a “Buy” rating and a $17.00 price objective on the stock. The consensus estimate for Nuvation Bio’s current full-year earnings is ($0.36) per share. HC Wainwright also issued estimates for Nuvation Bio’s Q4 2026 earnings at ($0.06) EPS and FY2026 earnings at ($0.35) EPS.

Nuvation Bio (NYSE:NUVB) last released its quarterly earnings data on Monday, November 3rd. The company reported ($0.16) EPS for the quarter, beating the consensus estimate of ($0.17) by $0.01. Nuvation Bio had a negative return on equity of 54.99% and a negative net margin of 813.07%.The firm had revenue of $13.12 million during the quarter, compared to the consensus estimate of $7.48 million.

A number of other research analysts have also weighed in on the stock. JMP Securities set a $10.00 price objective on shares of Nuvation Bio in a research note on Thursday, November 20th. B. Riley began coverage on shares of Nuvation Bio in a report on Wednesday, November 19th. They issued a “buy” rating and a $12.00 target price on the stock. UBS Group initiated coverage on Nuvation Bio in a research note on Wednesday, January 7th. They set a “neutral” rating and a $10.00 price target for the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Nuvation Bio in a report on Wednesday, October 8th. Finally, Citizens Jmp raised their target price on Nuvation Bio from $8.00 to $10.00 and gave the company a “market outperform” rating in a report on Thursday, November 20th. One equities research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $10.40.

Nuvation Bio Stock Performance

NYSE NUVB opened at $6.14 on Wednesday. The company has a market cap of $2.10 billion, a P/E ratio of -9.59 and a beta of 1.54. The company has a fifty day simple moving average of $7.69 and a 200 day simple moving average of $4.73. The company has a current ratio of 8.48, a quick ratio of 8.39 and a debt-to-equity ratio of 0.14. Nuvation Bio has a 12-month low of $1.54 and a 12-month high of $9.75.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the business. Highline Wealth Partners LLC bought a new stake in shares of Nuvation Bio during the 2nd quarter worth $25,000. Rangeley Capital LLC purchased a new stake in Nuvation Bio during the second quarter worth about $25,000. Parallel Advisors LLC increased its holdings in Nuvation Bio by 51.9% during the third quarter. Parallel Advisors LLC now owns 7,597 shares of the company’s stock worth $28,000 after buying an additional 2,597 shares during the last quarter. Cetera Investment Advisers bought a new stake in Nuvation Bio in the second quarter worth about $29,000. Finally, Captrust Financial Advisors purchased a new position in Nuvation Bio in the second quarter valued at about $32,000. Institutional investors own 61.67% of the company’s stock.

Insider Transactions at Nuvation Bio

In other news, insider Gary Hattersley sold 100,000 shares of the company’s stock in a transaction that occurred on Monday, October 27th. The stock was sold at an average price of $5.02, for a total value of $502,000.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Dongfang Liu sold 150,000 shares of the stock in a transaction that occurred on Monday, December 1st. The shares were sold at an average price of $7.82, for a total value of $1,173,000.00. Following the sale, the insider directly owned 18,000 shares of the company’s stock, valued at $140,760. The trade was a 89.29% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 320,000 shares of company stock valued at $2,050,800 over the last ninety days. 29.93% of the stock is currently owned by insiders.

Nuvation Bio Company Profile

Nuvation Bio is a clinical-stage biotechnology company dedicated to discovering and developing small-molecule therapies for patients with cancer. The company employs an integrated research and development platform that spans target identification, preclinical evaluation, process chemistry, and early-stage clinical trials. By centralizing these capabilities, Nuvation Bio aims to accelerate the translation of promising drug candidates from laboratory research to first-in-human studies.

The company’s pipeline comprises multiple oncology programs, with small-molecule kinase inhibitors and targeted agents in Phase 1 development for both hematologic malignancies and solid tumors.